title: Weather/temperature-sensitive vasomotor rhinitis may be refractory to intranasal corticosteroid treatment.
abstract: Vasomotor rhinitis (VMR) is a common but poorly understood disorder of which there are two major subgroups: VMR(w/t), triggered by weather/temperature and VMR(ir), triggered by airborne irritants. No specific biological pathways or specific treatments for VMR(w/t) or VMR(ir) have been identified. However, intranasal corticosteroids (INSs) are effective in treating many forms of nonallergic rhinitis that include these conditions. A recently introduced INS with established efficacy in allergic rhinitis and enhanced affinity, fluticasone furoate, may possess the potency and safety profile required to treat chronic VMR(w/t). Two replicate studies (FFR30006 and FFR30007) were conducted in six countries to evaluate the efficacy and safety of fluticasone furoate nasal spray in subjects with VMR(w/t). After a 7- to 14-day screening period, subjects (n = 699) with symptomatic VMR(w/t) received fluticasone furoate, 110 mug q.d. or placebo for 4 weeks in these two randomized, double-blind, parallel-group studies. Subjects rated their nasal symptoms (congestion, rhinorrhea, and postnasal drip) twice daily on a 4-point categorical scale and evaluated their overall response to treatment at study end. Fluticasone furoate did not significantly improve daily reflective total nasal symptom scores, the primary end point, versus placebo (p = 0.259) and there was no improvement in any other measure of efficacy. The active treatment was well tolerated. Fluticasone furoate was not effective in treating subjects with a newly defined condition, weather-sensitive VMR. These unexpected results suggest that VMR(w/t) is a distinct subgroup of VMR that is refractory to treatment with INSs. Additional study of other treatments for VMR(w/t) (including INSs) is warranted.
authors.affiliation: Biogenics Research Institute, San Antonio, Texas 78229, USA. robert.jacobs7025@sbcglobal.net
authors.forename: Robert
authors.initials: R
authors.lastname: Jacobs
authors.forename: Philip
authors.initials: P
authors.lastname: Lieberman
authors.forename: Edward
authors.initials: E
authors.lastname: Kent
authors.forename: MaryJane
authors.initials: M
authors.lastname: Silvey
authors.forename: Nicholas
authors.initials: N
authors.lastname: Locantore
authors.forename: Edward E
authors.initials: EE
authors.lastname: Philpot
mesh_terms: D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000730:Androstadienes / Q000008:administration & dosage* / Q000009:adverse effects; D002170:Canada; D002648:Child; D004351:Drug Resistance / Q000276:immunology; D005060:Europe; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015508:Nasal Obstruction / Q000188:drug therapy / Q000276:immunology; D012223:Rhinitis, Vasomotor / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology; D013696:Temperature; D016896:Treatment Outcome; D014481:United States; D014887:Weather
chemical_list: D000730:Androstadienes; C523187:fluticasone furoate